- Trials with a EudraCT protocol (1,169)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,169 result(s) found for: Levels of biomarkers.
Displaying page 7 of 59.
EudraCT Number: 2014-003142-27 | Sponsor Protocol Number: RALAM | Start Date*: 2015-07-13 |
Sponsor Name:Fundació Clinic per a la Recerca Biomédica | ||
Full Title: A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when replacing standard com... | ||
Medical condition: Chronic HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000986-60 | Sponsor Protocol Number: RALAM-Roll-Over | Start Date*: 2017-10-11 | |||||||||||
Sponsor Name:Fundació Clinic per a la Recerca Biomédica | |||||||||||||
Full Title: Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of 3TC (150 mg BID) plus Raltegravir (400 mg BID) switching to 3... | |||||||||||||
Medical condition: Patients of RALAM study (NCT02284035) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003262-25 | Sponsor Protocol Number: MK8259-022 | Start Date*: 2014-12-12 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: An open label, single group assignment design study to correlate soluble ST2 with clinical, endoscopic and histological activity in moderate to severe Ulcerative Colitis patients under golimumab | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005747-29 | Sponsor Protocol Number: BP20843 | Start Date*: 2007-03-14 | ||||||||||||||||
Sponsor Name:F. HOFFMANN-LA ROCHE LTD | ||||||||||||||||||
Full Title: Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs | ||||||||||||||||||
Medical condition: Primary hypercholesterolemia or mixed dyslipidemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004036-19 | Sponsor Protocol Number: Uni-Koeln-1754 | Start Date*: 2015-04-21 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: GHSG-AFM13 An open-label, randomized, multicenter phase II trial with AFM13 in patients with relapsed or refractory Hodgkin Lymphoma | |||||||||||||
Medical condition: Activity of AFM13 in patients with relapsed/refractory Hodgkin lymphoma after failure of standard therapy including the anti-CD30 immunoconjugate brentuximab vedotin (BV). In this heavily pretreate... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005091-13 | Sponsor Protocol Number: SMS | Start Date*: 2008-03-06 | |||||||||||
Sponsor Name:Guy's & St Thomas' NHS Foundation Trust
[...]
1. Guy's & St Thomas' NHS Foundation Trust
2. Kings College London (University) |
|||||||||||||
Full Title: Phase II study of sorafenib in malignant mesothelioma previously treated with platinum-based chemotherapy | |||||||||||||
Medical condition: Malignant Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002212-16 | Sponsor Protocol Number: CAIN457ADE03 | Start Date*: 2015-01-22 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Exploratory study on the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers in patients with moderate to severe plaque-type psoriasis treated with subcutaneous secukinumab (... | |||||||||||||
Medical condition: chronic moderate to severe plaque type psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004980-30 | Sponsor Protocol Number: DG-031-203 | Start Date*: 2005-01-14 |
Sponsor Name:deCODE genetics ehf. | ||
Full Title: A single-site, open-label, randomised dose finding study to examine safety, tolerability and dose-related effects of DG-031 on inflammatory biomarkers in serum of FLAP and/or LTA4 hydrolase haploty... | ||
Medical condition: Ischaemic heart disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IS (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002632-24 | Sponsor Protocol Number: P160915 | Start Date*: 2018-11-13 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: Therapeutic plasma exchange, rituximab and intravenous immunoglobulins (IVIg) for severe acute exacerbation of idiopathic pulmonary fibrosis admitted in ICU: an open, randomized, controlled trial | ||
Medical condition: severe acute exacerbation of idiopathic pulmonary fibrosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000893-68 | Sponsor Protocol Number: LAED001 | Start Date*: 2012-11-15 |
Sponsor Name:Fundació Clinic per a la Recerca Biomèdica | ||
Full Title: Differences in endothelial function amongst Sitagliptin and Liraglutide Users: A randomized, open-label, parallel-group and active controlled trial | ||
Medical condition: type 2 diabetes patients not well controlled at the maximum tolerated dose of metformin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001375-32 | Sponsor Protocol Number: PreToVid | Start Date*: 2020-04-03 |
Sponsor Name:UMCG | ||
Full Title: Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial | ||
Medical condition: Hypoxia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002909-25 | Sponsor Protocol Number: 74310 | Start Date*: 2020-10-21 |
Sponsor Name:Amsterdam University Medical Centers | ||
Full Title: Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: a randomized phase II proof-of-concept study | ||
Medical condition: oesophageal adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005854-90 | Sponsor Protocol Number: ANX005-CAD-01 | Start Date*: 2021-02-11 |
Sponsor Name:Annexon, Inc. | ||
Full Title: A Phase 2, Single-Center, Open-Label, Repeat-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Intravenous ANX005 in Participants with Primary... | ||
Medical condition: Primary Cold Agglutinin Disease (CAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002940-22 | Sponsor Protocol Number: STARDUST | Start Date*: 2021-01-13 | |||||||||||
Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli" | |||||||||||||
Full Title: EFFECTS OF THE GLP-1 RECEPTOR AGONIST LIRAGLUTIDE ON LOWER LIMB PERFUSION IN PEOPLE WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A RANDOMIZED CONTROLLED TRIAL | |||||||||||||
Medical condition: Peripheral Artery Disease and type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002202-43 | Sponsor Protocol Number: Empa_MIBG | Start Date*: 2021-04-28 | |||||||||||
Sponsor Name:AOU FEDERICO II | |||||||||||||
Full Title: Effects of empagliflozin on cardiac remodeling and myocardial sympathetic nervous system in diabetic patients affected by chronic heart failure | |||||||||||||
Medical condition: diabetes mellitus and heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011382-80 | Sponsor Protocol Number: | Start Date*: 2009-06-22 |
Sponsor Name:Nottingham University Hospital | ||
Full Title: Intravenous Iron: biomarkers and treatment strategies in anaemic Colorectal cancer patients. | ||
Medical condition: Anaemia (specifically related to surgical pathology) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005084-29 | Sponsor Protocol Number: 1 | Start Date*: 2006-03-23 |
Sponsor Name:Chief Scientitst Office | ||
Full Title: The effect of intensive lipid lowering on markers of inflammation in patients with stable coronary artery disease. | ||
Medical condition: Patients with cardiovascular risk factors and stable coronary artery disease, with a fasting total cholesterol level ≥5 mmol/l. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003671-30 | Sponsor Protocol Number: VHL-HOPE-2014-1 | Start Date*: 2014-10-31 |
Sponsor Name:ALIANZA ESPAÑOLA DE FAMILIAS DE VON HIPPEL-LINDAU | ||
Full Title: Therapeutic effect of propranolol in a series of patients with von Hippel-Lindau disease and retinal hemangioblastomas in short, medium and long term treatment. | ||
Medical condition: VON HIPPEL-LINDAU DISEASE | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001655-13 | Sponsor Protocol Number: NL2021-8172 | Start Date*: 2021-04-01 |
Sponsor Name:Radboudumc | ||
Full Title: SARS-CoV2 vaccination and activation of the coagulation system | ||
Medical condition: Coronavirus disease 2019 and thromboembolism | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002978-52 | Sponsor Protocol Number: CNTO1959HDS2002 | Start Date*: 2019-07-16 |
Sponsor Name:Universitair Medisch Centrum Groningen | ||
Full Title: Guselkumab for hidradenitis suppurativa, a mode of action study. | ||
Medical condition: Hidradenitis suppurativa | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
